FundedIQ

Funded Biotechnology Startups in Berkeley

The disclosed funding amounts in this Berkeley biotechnology slice cluster tightly below the top end, with Carmot Therapeutics’ $150M round (2023-05-25) th…

The disclosed funding amounts in this Berkeley biotechnology slice cluster tightly below the top end, with Carmot Therapeutics’ $150M round (2023-05-25) the largest disclosed amount. The next-largest disclosed rounds sit at $125M (Caribou Biosciences, 2023-07-13) and $90M (Perfect Day, 2024-01-05), while most other disclosed entries fall into lower- and mid–tens of millions. One clear outlier on the downside is BioGlyph’s “undisclosed” round (2024-08-06), which breaks the otherwise disclosed-amount comparison.

Dates span 2020-12-01 (Newomics) through 2025-11-03 (Kyverna Therapeutics), and several rounds cluster in 2023: multiple entries from May–October 2023 include Carmot Therapeutics ($150M, 2023-05-25), Caribou Biosciences ($125M, 2023-07-13), and Pow.bio ($10M, 2023-10-04). Stage labeling is mixed: “Series Unknown” appears in 7 of 20 rows, and “Seed” appears in 4 of 20 rows, with additional presence of Series A (4 of 20 rows) and later stages such as Series E (2 of 20 rows). Geography is consistently Berkeley, California across all 20 rows.

Most recent rounds

20 shown
K
Kyverna Therapeutics
Berkeley, United States · Biotechnology
Series Unknown · Nov 2025
$25M
E
EditPep
Berkeley, United States · Biotechnology
Series Unknown · Dec 2024
$8.2M
S
SonALAsense
Berkeley, United States · Biotechnology
Series Unknown · Dec 2024
$46M
B
BioGlyph
Berkeley, United States · Biotechnology
Series Unknown · Aug 2024
Undisclosed
P
Perfect Day
Berkeley, United States · Biotechnology
Series E · Jan 2024
$90M
A
Actym Therapeutics, Inc.
Berkeley, United States · Biotechnology
Series A · Oct 2023
$26M
P
Pow.bio
Berkeley, United States · Biotechnology
Series A · Oct 2023
$9.5M
N
Novel Farms, Inc.
Berkeley, United States · Biotechnology
Series Unknown · Sep 2023
$1.0M
C
Caribou Biosciences
Berkeley, United States · Biotechnology
Series Unknown · Jul 2023
$125M
C
Carmot Therapeutics
Berkeley, United States · Biotechnology
Series E · May 2023
$150M
C
Channel Medsystems
Berkeley, United States · Biotechnology
Series Unknown · May 2023
$10M
F
Flightpath Biosciences
Berkeley, United States · Biotechnology
Series Unknown · Feb 2023
$1.1M
V
Valitor
Berkeley, United States · Biotechnology
Series B · Oct 2022
$28M
L
Lygos
Berkeley, United States · Biotechnology
Venture - Series Unknown · Apr 2022
$160M
M
MeliBio
Berkeley, United States · Biotechnology
Seed · Mar 2022
$5.7M
N
Nodexus
Berkeley, United States · Biotechnology
Series A · Dec 2021
$30M
F
Fauna Bio
Berkeley, United States · Biotechnology
Seed · Sep 2021
$9.0M
S
StimScience
Berkeley, United States · Biotechnology
Seed · Apr 2021
$6.0M
N
New Age Meats
Berkeley, United States · Biotechnology
Seed · Feb 2021
$2.0M
N
Newomics
Berkeley, United States · Biotechnology
· Dec 2020
$7.9M

Related listings

Frequently asked

Which company has the largest disclosed round in this Berkeley biotechnology list, and how far ahead is it of the next-largest disclosed amount?

Carmot Therapeutics holds the largest disclosed amount at $150M on 2023-05-25. The next-largest disclosed rounds are $125M (Caribou Biosciences, 2023-07-13) and $90M (Perfect Day, 2024-01-05), so the top round is materially above the rest.

Do the most recent rounds concentrate in a narrow time window (e.g., within the last ~1 year) or spread out?

The most recent entry is Kyverna Therapeutics on 2025-11-03, followed by two more entries in late 2024 (EditPep 2024-12-19 at $8M; SonALAsense 2024-12-12 at $46M). Beyond that, the list shows heavier concentration in 2023, including multiple high-ticket rounds such as Carmot Therapeutics ($150M, 2023-05-25) and Caribou Biosciences ($125M, 2023-07-13).

Is “Series Unknown” common enough to affect how analysts should segment these funding rounds by stage?

Yes. “Series Unknown” appears in 7 of 20 rows, including Kyverna Therapeutics (2025-11-03, $25M) and SonALAsense (2024-12-12, $46M). Seed shows up in 4 of 20 rows (e.g., MeliBio $6M on 2022-03-17; Fauna Bio $9M on 2021-09-21), and Series A also appears 4 of 20 rows (e.g., Actym Therapeutics $26M on 2023-10-18; Pow.bio $10M on 2023-10-04).

Are there notable outliers beyond the top end, such as very small disclosed rounds or undisclosed amounts?

BioGlyph’s 2024-08-06 round is “undisclosed,” which prevents direct sizing in comparisons. Among disclosed amounts, the smallest shown is $1M (Novel Farms, Inc., 2023-09-28; and Flightpath Biosciences, 2023-02-15), creating a wide spread from the $150M max to the $1M floor.

Within this dataset, are later-stage rounds (Series B/E) clustered around specific years, or distributed?

Later stages appear, but not densely: Series E is present twice (Perfect Day $90M on 2024-01-05; Carmot Therapeutics $150M on 2023-05-25). Series B appears once (Valitor $28M on 2022-10-05), while earlier labels like Seed and Series A show more repetition across 2021–2023 (e.g., Fauna Bio $9M on 2021-09-21; Nodexus $30M on 2021-12-16; Actym Therapeutics $26M on 2023-10-18).

Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.